论文部分内容阅读
继2015年8月初广东一患儿父亲在网上发布求放线菌素D帖子后,9月15日,一则“7.8元一盒的婴儿痉挛症常用药注射用促皮质素(ACTH)一药难求,黑市炒到4000元”的消息再度引发社会关注。上述两种药品为何紧缺,在媒体的调查中,大致可窥见一斑。据悉,放线菌素D的紧缺是因为该药品生产厂家海正药业“企业重组后生产线调整尚需工艺验证等工作”暂停生产,从而导致全国性断货。
Following the early August 2015 Guangdong a father released online actinomycin D post, September 15, a “7.8 yuan a box of infantile spasms commonly used for injection of corticotropin (ACTH) a Drug demand, the black market speculation 4000 yuan ”news again triggered social concern. Why the shortage of these two drugs in the media survey can be roughly glimpsed. It is reported that the scarcity of actinomycin D is because the drug manufacturer Hisun Pharmaceutical “restructuring of the production line after the reorganization of enterprises still need to verify the work process ” to suspend production, resulting in a national out of stock.